HGF and cancer: HGF/c-Met signaling pathways are deregulated in human cancer by overexpression of HGF or c-Met, gene amplification, mutational activation of c-Met, downregulation of Met-targeted miRNA, binding to other ligands, autocrine signaling or overly high levels of HGF [34].